

**Supplementary Table 1 Summary of the original studies describing iMSC production in five categories of protocols, as indicated**

REFERENCES	MS	EB	SD	PI	PL
Lian Q. et al. 2010 <sup>[41]</sup>	X				
Giuliani M. et al. 2011 <sup>[42]</sup>	X				
Ahfeldt T, et al. 2012 <sup>[56]</sup>		X			
Chen YS et al. 2012* <sup>[57]</sup>		X		X	
L.G. Villa-Diaz et al. 2012 <sup>[58]</sup>		X			
Liu Y. et al. 2012 <sup>[43]</sup>	X				
Wei H. et al. 2012* <sup>[59]</sup>		X	X	X	
Shao K. et al. 2013 <sup>[60]</sup>		X			
Zou L. et al. 2013 <sup>[40]</sup>	X				
Frobel J. et al 2014 <sup>[71]</sup>					X
Fukuta et al. 2014* <sup>[66]</sup>			X	X	
Hynes et al. 2014 <sup>[45]</sup>	X				
Jeong J. et al. 2014* <sup>[46]</sup>	X	X		X	
Miao Q. et al. 2014 <sup>[61]</sup>		X			
Tang M. et al. 2014 <sup>[21]</sup>		X			
Hu GW. et al. 2015 <sup>[47]</sup>	X				
Kang R. et al 2015 <sup>[48]</sup>	X				
Luzzani C. et al. 2015 <sup>[72]</sup>					X
Zhang J. et al. 2015 <sup>[23]</sup>	X				
Zhao et al. 2015 <sup>[67]</sup>				X	
Lian Q. et al. 2016 <sup>[49]</sup>	X				
Ouchi T. et al. 2016 <sup>[65]</sup>			X		
Gao WX et al. 2017 <sup>[50]</sup>	X				
Sheyn D. et al. 2017 <sup>[20]</sup>		X			
Eto S. et al 2018* <sup>[55]</sup>		X	X		
Nachlas ALY et al. 2018* <sup>[51]</sup>	X	X			
Wang D. et al. 2018 <sup>[52]</sup>	X				
Wang LT et al. 2018 <sup>[53]</sup>	X				
McGrath et al. 2019* <sup>[54]</sup>	X				X
Mitsuzawa S. et al. 2019 <sup>[64]</sup>			X		
Karam M. et al. 2020 <sup>[62]</sup>		X			
Huang X. et al. 2020 <sup>[63]</sup>		X			
<b>TOTAL</b>	16/32	13/32	5/32	5/32	3/32

MS : MSC Switch, EB : Embryoid Bodies, SD: Specific Differentiation, PI: pathway inhibitor, PL: platelet lysate.

**Supplementary Table 2 Culture medium, supplements, and coatings**

1. Medium, 2. Supplements, 3. Coatings.

A. MSC Switch, B. EB, C. Specific Differentiation, D. Pathway Inhibitor, E. Platelet Lysate.

**1A**

	$\alpha$ -MEM	DMEM	DMEM/F12	HG-DMEM	KO DMEM	LG-DMEM
Lian Q. et al. 2010 <sup>[41]</sup>					X	
Giuliani M. et al. 2011 <sup>[42]</sup>			X			
Liu Y. et al. 2012 <sup>[43]</sup>	X					
Zou L. et al. 2013 <sup>[44]</sup>						X
Hynes et al. 2014 <sup>[45]</sup>	X					
Jeong J. et al. 2014 <sup>*[46]</sup>			X			
Hu GW. et al. 2015 <sup>[47]</sup>						X
Kang R. et al 2015 <sup>[48]</sup>						X
Zhang J. et al. 2015 <sup>[23]</sup>						X
Lian Q. et al. 2016 <sup>[49]</sup>		X			X	
Gao WX et al. 2017 <sup>[50]</sup>	X			X		
Nachlas ALY et al. 2018 <sup>*[51]</sup>					X	
Wang D. et al. 2018 <sup>[52]</sup>	X			X		
Wang LT et al. 2018 <sup>[53]</sup>						X
McGrath et al. 2019 <sup>[54]</sup>	X				X	
TOTAL (15 references)	5/15	1/15	2/15	2/15	4/15	5/15

**1B**

	$\alpha$ -MEM	DMEM	DMEM/F12	HG-DMEM	IMDM	KO DMEM	LG-DMEM	MEF medium
Ahfeldt T, et al. 2012 <sup>[56]</sup>		X						
Chen YS et al. 2012 <sup>*[57]</sup>		X						
L.G. Villa-Diaz et al. 2012 <sup>[58]</sup>	X							
Wei H. et al. 2012 <sup>*[59]</sup>		X		X				
Shao K. et al. 2013 <sup>[60]</sup>						X		
Jeong J. et al. 2014 <sup>*[46]</sup>			X					
Miao Q. et al. 2014 <sup>[61]</sup>		X						
Tang M. et al. 2014 <sup>[1]</sup>		X	X					X
Sheyn D. et al. 2017 <sup>[21]</sup>		X			X			
Eto S. et al 2018 <sup>*[55]</sup>	X		X					
Nachlas ALY et al. 2018 <sup>*[51]</sup>						X		
Karam M. et al. 2020 <sup>[62]</sup>							X	
Huang X. et al. 2020 <sup>[63]</sup>	X							
TOTAL (13 references)	3/13	6/13	3/13	1/13	1/13	2/13	1/13	1/13

**1C**

	DMEM	HG-DMEM	STK2	DMEM/F12	$\alpha$ -MEM	Neurobasal medium	IMDM
Wei H. et al. 2012*[59]	X	X					
Fukuta et al. 2014*[66]			X		X		X
Ouchi T. et al. 2016[65]				X		X	
Eto S. et al 2018*[55]				X	X		
Mitsuzawa S. et al. 2019[64]	X						X
TOTAL	2/5	1/5	1/5	2/5	2/5	1/5	2/5

**1D**

	STK2	$\alpha$ -MEM	DMEM	KO DMEM	HG-DMEM	Ham's F12	IMDM
Chen YS et al. 2012*[57]			X				
Wei H. et al. 2012*[59]			X			X	
Fukuta et al. 2014*[66]	X	X				X	X
Jeong J. et al. 2014*[46]	X	X				X	X
Zhao Q. et al. 2015[67]				X	X		
TOTAL (5 references)	2/15	2/15	2/15	1/15	1/15	3/15	2/15

**1E**

	$\alpha$ -MEM	DMEM	KO DMEM
Frobel J. et al 2014[71]		X	
Luzzani C. et al. 2015[72]	X		
McGrath et al. 2019[54]			X
TOTAL (3 references)	1/3	1/3	1/3

## 2A

REFERENCES	AAP2	APM	B-merc	BSA	dexamethasone	EGF	FBS	FGF	HEPES	ITS	KOSR	L-Gluta	NEAA	PDGF	P/S	SB431542	sodium pyru
Lian Q. et al. 2010 <sup>[41]</sup>						X		X			X			X			
Giuliani M. et al. 2011 <sup>[42]</sup>			X				X	X				X	X		X		
Liu Y. et al. 2012 <sup>[43]</sup>		X			X		X					X	X		X		
Zou L. et al. 2013 <sup>[44]</sup>							X					X					
Hynes et al. 2014 <sup>[45]</sup>	X						X		X			X	X		X		X
Jeong J. et al. 2014* <sup>[46]</sup>				X			X			X	X				X	X	
Hu GW. et al. 2015 <sup>[47]</sup>							X					X					
Kang R. et al 2015 <sup>[48]</sup>							X					X			X		
Zhang J. et al. 2015 <sup>[23]</sup>							X					X	X		X		
Lian Q. et al. 2016 <sup>[49]</sup>						X	X	X			X			X			
Gao WX et al. 2017 <sup>[50]</sup>	X					X	X	X				X	X		X		X
Nachlas ALY et al. 2018* <sup>[51]</sup>			X				X					X	X		X		
Wang D. et al. 2018 <sup>[52]</sup>	X					X	X	X				X	X		X		X
Wang LT et al. 2018 <sup>[53]</sup>							X					X			X		
McGrath et al. 2019 <sup>[54]</sup>							X	X				X	X				
TOTAL (15 references)	3/15	1/15	2/15	1/15	1/15	4/15	14/15	6/15	1/15	1/15	3/15	14/15	8/15	2/15	10/15	1/15	3/15

## 2B

	Activin A	BSA	B-merc	BMP4	CTK	FBS	FGF	gentami	ITS	KOSR	L-Gluta	LiCl	NEAA	P/S	PSA	RA	SB203580	SB431542	TGF-B1
Ahfeldt T. et al. 2012 <sup>[56]</sup>						X	X				X								
Chen YS et al. 2012* <sup>[57]</sup>						X		X			X			X				X	
L.G. Villa-Diaz et al. 2012 <sup>[58]</sup>						X	X				X		X						
Wei H. et al. 2012* <sup>[59]</sup>			X			X			X		X		X				X		
Shao K. et al. 2013 <sup>[60]</sup>			X			X					X		X						
Jeong J. et al. 2014* <sup>[46]</sup>		X				X			X	X				X				X	
Miao Q. et al. 2014 <sup>[61]</sup>						X													
Tang M. et al. 2014 <sup>[21]</sup>			X			X				X	X		X	X					
Sheyn D. et al. 2017 <sup>[20]</sup>			X			X				X	X		X	X	X				X
Eto S. et al 2018* <sup>[55]</sup>	X		X	X	X	X	X				X	X	X	X		X			
Nachlas ALY et al. 2018* <sup>[51]</sup>			X			X					X		X	X					
Karam M. et al. 2020 <sup>[62]</sup>						X	X							X		X			
Huang X. et al. 2020 <sup>[63]</sup>							X												
TOTAL (13 references)	1/13	1/13	6/13	1/13	1/13	12/13	5/13	1/13	2/13	3/13	9/13	1/13	7/13	7/13	1/13	2/13	1/13	2/13	1/13

## 2C

	Activin A	apo-tran	B-merc	BMP4	BSA	CHIR	CTK	EGF	FBS	FGF	Gem21 Neuro	insulin	ITS	LiCl	lipid conc	monothiog	NEAA	N2 sup	P/S	RA	SB203580	SB431542
Wei H. et al. 2012* <sup>[59]</sup>			X						X				X				X				X	
Fukuta et al. 2014* <sup>[66]</sup>		X			X	X			X			X			X	X			X			X
Ouchi T. et al. 2016 <sup>[65]</sup>								X		X	X	X						X	X			
Eto S. et al 2018* <sup>[55]</sup>	X		X	X			X		X	X				X					X	X		
Mitsuzawa S. et al. 2019 <sup>[64]</sup>		X			X	X			X	X		X			X	X			X			X
TOTAL (5 references)	1/5	2/5	2/5	1/5	2/5	2/5	1/5	1/5	4/5	3/5	1/5	3/5	1/5	1/5	2/5	2/5	1/5	1/5	4/5	1/5	1/5	2/5

## 2D

	apo-tran	BSA	B-merc	CHIR	EGF	FBS	FGF	gentami	insulin	ITS	L-Gluta	lipid conc	monothioglycerol	NEAA	P/S	SB 203580	SB431542
Chen YS et al. 2012* <sup>[57]</sup>						X		X			X				X		X
Wei H. et al. 2012* <sup>[59]</sup>			X			X				X	X			X		X	
Fukuta et al. 2014* <sup>[66]</sup>	X	X		X		X			X			X	X		X		X
Jeong J. et al. 2014* <sup>[46]</sup>		X				X				X					X		X
Zhao et al. 2015 <sup>[67]</sup>			X		X		X				X			X	X		X
TOTAL (5 references)	1/5	2/5	2/5	1/5	1/5	4/5	1/5	1/5	1/5	1/5	3/5	1/5	1/5	2/5	4/5	1/5	4/5

## 2E

	B-merc	FBS	FGF	heparin	hPL	L-Gluta	NEAA	P/S
Frobel J. et al 2014 <sup>[71]</sup>				X	X	X		X
Luzzani C. et al. 2015 <sup>[72]</sup>		X		X	X			X
McGrath et al. 2019 <sup>[54]</sup>	X	X	X	X	X	X	X	X
TOTAL (3 references)	1/3	2/3	1/3	3/3	3/3	2/3	1/3	3/3

**3A**

	Collagen	Gelatin	Matrigel	Ø
Lian Q. et al. 2010 <sup>[41]</sup>		X		
Giuliani M. et al. 2011 <sup>[42]</sup>				X
Liu Y. et al. 2012 <sup>[43]</sup>	X			
Zou L. et al. 2013 <sup>[44]</sup>				X
Hynes et al. 2014 <sup>[45]</sup>		X		
Jeong J. et al. 2014* <sup>[46]</sup>			X	
Hu GW. et al. 2015 <sup>[47]</sup>		X		
Kang R. et al 2015 <sup>[48]</sup>		X		
Zhang J. et al. 2015 <sup>[23]</sup>		X		
Lian Q. et al. 2016 <sup>[49]</sup>		X		
Gao WX et al. 2017 <sup>[50]</sup>		X		
Nachlas ALY et al. 2018* <sup>[51]</sup>		X		
Wang D. et al. 2018 <sup>[52]</sup>		X		
Wang LT et al. 2018 <sup>[53]</sup>				X
McGrath et al. 2019 <sup>[54]</sup>		X		
TOTAL (15 references)	1/15	10/15	1/15	3/15

**3B**

	Collagen	Gelatin	Matrigel	poly- HEMA	Ø
Ahfeldt T, et al. 2012 <sup>[56]</sup>		X			
Chen YS et al. 2012* <sup>[57]</sup>					X
L.G. Villa-Diaz et al. 2012 <sup>[58]</sup>		X			
Wei H. et al. 2012* <sup>[59]</sup>					X
Shao K. et al. 2013 <sup>[60]</sup>		X			
Jeong J. et al. 2014* <sup>[46]</sup>			X		
Miao Q. et al. 2014 <sup>[61]</sup>					X
Tang M. et al. 2014 <sup>[21]</sup>		X			
Sheyn D. et al. 2017 <sup>[20]</sup>		X		X	
Eto S. et al 2018* <sup>[55]</sup>	X	X			
Nachlas ALY et al. 2018* <sup>[51]</sup>		X			
Karam M. et al. 2020 <sup>[62]</sup>		X	X		
Huang X. et al. 2020 <sup>[63]</sup>		X			
TOTAL (13 references)	1/13	9/13	2/13	1/13	3/13

**3C**

	Collagen	Fibronectin	Gelatin	Ø
Wei H. et al. 2012* <sup>[59]</sup>			X	
Fukuta et al. 2014* <sup>[66]</sup>		X		
Ouchi T. et al. 2016 <sup>[65]</sup>				X
Eto S. et al 2018* <sup>[55]</sup>	X			
Mitsuzawa S. et al. 2019 <sup>[64]</sup>		X		
TOTAL (5 references)	1/5	2/5	1/5	1/5

**3D**

	Fibronectin	Matrigel	Ø
Chen YS et al. 2012* <sup>[57]</sup>		X	
Wei H. et al. 2012* <sup>[59]</sup>			X
Fukuta et al. 2014* <sup>[66]</sup>	X		
Jeong J. et al. 2014* <sup>[46]</sup>			X
Zhao et al. 2015 <sup>[67]</sup>		X	
TOTAL (5 references)	1/5	2/5	2/5

**3E**

	Gelatin	Matrigel
Frobel J. et al 2014 <sup>[71]</sup>	X	X
Luzzani C. et al. 2015 <sup>[72]</sup>		X
McGrath et al. 2019 <sup>[54]</sup>	X	
TOTAL (3 references)	2/3	2/3

**Supplementary Table 3 Cell type used to obtain iPSCs used in protocol studies to produce MSCs**

Cell Type	Fraction	%	References
dermal fibroblast	12/25	40%	Lian Q. et al. 2010 <sup>[41]</sup> L.G. Villa-Diaz et al. 2012 <sup>[58]</sup> Wei H. et al. 2012 <sup>[59]</sup> Zou L. et al. 2013 <sup>[44]</sup> Miao Q. et al. 2014 <sup>[61]</sup> Kang R. et al 2015 <sup>[48]</sup> Ouchi T. et al. 2016 <sup>[65]</sup> Sheyn D. et al. 2017 <sup>[20]</sup> Eto S. et al 2018 <sup>[55]</sup> McGrath et al. 2019 <sup>[54]</sup>
PBMC	4/25	13%	Wang LT et al. 2018 <sup>[53]</sup> Karam M. et al. 2020 <sup>[62]</sup> Huang X. et al. 2020 <sup>[63]</sup>
amniocyte	3/25	10%	Giuliani M. et al. 2011 <sup>[42]</sup> Gao WX et al. 2017 <sup>[50]</sup> Wang D. et al. 2018 <sup>[52]</sup>
BM	3/25	10%	Frobel J. et al 2014 <sup>[71]</sup> Tang M. et al. 2014 <sup>[21]</sup> McGrath et al. 2019 <sup>[54]</sup>
fetal endothelial	1/25	3%	Wang LT et al. 2018 <sup>[53]</sup>
foreskin fibroblast	2/25	7%	Luzzani C. et al. 2015 <sup>[72]</sup> Chen YS et al. 2012* <sup>[57]</sup>
lung fibroblast	1/25	3%	Chen YS et al. 2012* <sup>[57]</sup>
MSC	1/25	3%	Shao K. et al. 2013 <sup>[60]</sup>
PGF	1/25	3%	Hynes et al. 2014 <sup>[45]</sup>
PDL	1/25	3%	Hynes et al. 2014 <sup>[45]</sup>
urine-cell	1/25	3%	Gao WX et al. 2017 <sup>[50]</sup>

\* Indicates studies using protocols in more than one category



A: Positive markers. B: Negative markers.

REF	CD29	CD33	CD44	CD49(a)	CD49(d)	CD49(e)	CD49(f)	CD54	CD71	CD73	CD90	CD105	CD106	CD140 alpha	CD140(b)	CD144	CD146	CD166	CD172alpha	CD271	HLA-ABC	Sca1	αSMA+	Stro1
[89]																								
[90]																								
[17]			+							+	+	+					+	+						
[91]	+		+							+	+	+								+				
[19]										+	+	+												
[64]			+							+		+												
[92]			+	+		+				+		+						+						
[93]	+		+	+						+		+						+						
[94]																					+			
[95]			+							+	+	+						+						
[71]	+									+	+	+												
[41]			+	+		+				+		+						+						
[53]										+	+	+									+			
[96]	+										+													
[97]	+		+							+	+		+									+		
[45]										+	+	+	+				+	+						
[48]	+		+							+	+	+												
[67]			+							+	+	+						+						
[54]			+							+	+													
[58]										+	+	+						+						
[55]					+					+	+	+	+	+	+					+				
[72]	+			+	+	+	+			+	+	+						+	+	+				
[50]			+							+	+	+				+	+	+						
[66]			+							+		+												
[42]								+		+	+	+					+							
[43]										+	+	+					+	+						
[98]										+	+	+												
[99]			+							+	+	+									+			
[57]	+		+							+	+	+					+							
[62]	f		+							+	+	+												
[51]																								
[100]			+						+		+												+	
[61]			+	+		+				+		+						+						
[46]	+		+							+	+	+												
[47]	+	+								+	+	+												

[illegible]

**B**

[illegible]



- 8 Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci U S A* 2000; 97: 13625-13630 [PMID: 11087820 DOI: 10.1073/pnas.240309797]
- 9 Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci U S A* 2003; 100: 5807-5812 [PMID: 12716973 DOI: 10.1073/pnas.0937635100]
- 10 Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahimi J, Young M, Robey PG, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004; 364: 149-155 [PMID: 15246727 DOI: 10.1016/S0140-6736(04)16627-0]
- 11 Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. *J Immunol* 2009; 183: 7787-7798 [PMID: 19923445 DOI: 10.4049/jimmunol.0902318]
- 12 Gomez-Salazar M, Gonzalez-Galofre ZN, Casamitjana J, Crisan M, James AW, Péault B. Five Decades Later, Are Mesenchymal Stem Cells Still Relevant? *Front Bioeng Biotechnol* 2020; 8: 148 [PMID: 32185170 DOI: 10.3389/fbioe.2020.00148]
- 13 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]
- 14 El Haddad N. Mesenchymal Stem Cells: Immunology and Therapeutics Benefits. *IntechOpen* 2010 [DOI: 10.5772/21933]
- 15 Wang Y, Tian M, Wang F, Heng BC, Zhou J, Cai Z, Liu H. Understanding the Immunological Mechanisms of Mesenchymal Stem Cells in Allogeneic Transplantation: From the Aspect of Major Histocompatibility Complex Class I. *Stem Cells Dev* 2019; 28: 1141-1150 [PMID: 31215341 DOI: 10.1089/scd.2018.0256]
- 16 Gonzalo-Gil E, Pérez-Lorenzo MJ, Galindo M, Díaz de la Guardia R, López-Millán B, Bueno C, Menéndez P, Pablos JL, Criado G. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. *Arthritis Res Ther* 2016; 18: 77 [PMID: 27036118 DOI: 10.1186/s13075-016-0979-0]
- 17 Wang D, Niu L, Feng X, Yuan X, Zhao S, Zhang H, Liang J, Zhao C, Wang H, Hua B, Sun L. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. *Clin Exp Med* 2017; 17: 333-340 [PMID: 27270729 DOI: 10.1007/s10238-016-0427-0]
- 18 Moravej A, Geramizadeh B, Azarpira N, Zarnani AH, Yaghobi R, Kalani M, Khosravi M, Kouhpayeh A, Karimi MH. Mesenchymal stem cells increase skin graft survival time and up-regulate PD-L1 expression in splenocytes of mice. *Immunol Lett* 2017; 182: 39-49 [PMID: 28069488 DOI: 10.1016/j.imlet.2017.01.005]
- 19 Khan MA, Alanazi F, Ahmed HA, Shamma T, Kelly K, Hammad MA, Alawad AO, Assiri AM, Broering DC. iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants. *Stem Cell Res Ther* 2019; 10: 290 [PMID: 31547869 DOI: 10.1186/s13287-019-1397-4]
- 20 Sheyn D, Ben-David S, Shapiro G, De Mel S, Bez M, Ornelas L, Sahabian A, Sareen D, Da X, Pelled G, Tawackoli W, Liu Z, Gazit D, Gazit Z. Human Induced Pluripotent Stem Cells Differentiate Into Functional Mesenchymal Stem Cells and Repair Bone Defects. *Stem Cells Transl Med* 2016; 5: 1447-1460 [PMID: 27400789 DOI: 10.5966/sctm.2015-0311]

- 21 Tang M, Chen W, Liu J, Weir MD, Cheng L, Xu HH. Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration. *Tissue Eng Part A* 2014; 20: 1295-1305 [PMID: 24279868 DOI: 10.1089/ten.TEA.2013.0211]
- 22 Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. *Stem Cell Res Ther* 2012; 3: 25 [PMID: 22776206 DOI: 10.1186/scrt116]
- 23 Zhang J, Guan J, Niu X, Hu G, Guo S, Li Q, Xie Z, Zhang C, Wang Y. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. *J Transl Med* 2015; 13: 49 [PMID: 25638205 DOI: 10.1186/s12967-015-0417-0]
- 24 Wagner W, Ho AD. Mesenchymal stem cell preparations--comparing apples and oranges. *Stem Cell Rev* 2007; 3: 239-248 [PMID: 18074246 DOI: 10.1007/s12015-007-9001-1]
- 25 Elahi KC, Klein G, Avci-Adali M, Sievert KD, MacNeil S, Aicher WK. Human Mesenchymal Stromal Cells from Different Sources Diverge in Their Expression of Cell Surface Proteins and Display Distinct Differentiation Patterns. *Stem Cells Int* 2016; 2016: 5646384 [PMID: 26770208 DOI: 10.1155/2016/5646384]
- 26 Costa LA, Eiro N, Fraile M, Gonzalez LO, Saá J, Garcia-Portabella P, Vega B, Schneider J, Vizoso FJ. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. *Cell Mol Life Sci* 2021; 78: 447-467 [PMID: 32699947 DOI: 10.1007/s00018-020-03600-0]
- 27 Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. *BMC Med* 2013; 11: 146 [PMID: 23758701 DOI: 10.1186/1741-7015-11-146]
- 28 Xu L, Liu Y, Sun Y, Wang B, Xiong Y, Lin W, Wei Q, Wang H, He W, Wang B, Li G. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. *Stem Cell Res Ther* 2017; 8: 275 [PMID: 29208029 DOI: 10.1186/s13287-017-0716-x]
- 29 Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone* 2003; 33: 919-926 [PMID: 14678851 DOI: 10.1016/j.bone.2003.07.005]
- 30 Neri S, Borzì RM. Molecular Mechanisms Contributing to Mesenchymal Stromal Cell Aging. *Biomolecules* 2020; 10 [PMID: 32098040 DOI: 10.3390/biom10020340]
- 31 Liu J, Ding Y, Liu Z, Liang X. Senescence in Mesenchymal Stem Cells: Functional Alterations, Molecular Mechanisms, and Rejuvenation Strategies. *Front Cell Dev Biol* 2020; 8: 258 [PMID: 32478063 DOI: 10.3389/fcell.2020.00258]
- 32 Neri S. Genetic Stability of Mesenchymal Stromal Cells for Regenerative Medicine Applications: A Fundamental Biosafety Aspect. *Int J Mol Sci* 2019; 20 [PMID: 31096604 DOI: 10.3390/ijms20102406]
- 33 Al Jumah MA, Abumaree MH. The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). *Int J Mol Sci* 2012; 13: 9298-9331 [PMID: 22942767 DOI: 10.3390/ijms13079298]
- 34 Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. *Biol Res* 2012; 45: 269-277 [PMID: 23283436 DOI: 10.4067/S0716-97602012000300008]

- 35 Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. *Biomolecules* 2021; 11 [PMID: 33440772 DOI: 10.3390/biom11010082]
- 36 Squillaro T, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update. *Cell Transplant* 2016; 25: 829-848 [PMID: 26423725 DOI: 10.3727/096368915X689622]
- 37 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; 126: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]
- 38 Zacharias DG, Nelson TJ, Mueller PS, Hook CC. The science and ethics of induced pluripotency: what will become of embryonic stem cells? *Mayo Clin Proc* 2011; 86: 634-640 [PMID: 21719620 DOI: 10.4065/mcp.2011.0054]
- 39 Abdal Dayem A, Lee SB, Kim K, Lim KM, Jeon TI, Seok J, Cho AS. Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming. *Int J Mol Sci* 2019; 20 [PMID: 31003536 DOI: 10.3390/ijms20081922]
- 40 Steens J, Zuk M, Benchellal M, Bornemann L, Teichweyde N, Hess J, Unger K, Görgens A, Klump H, Klein D. In Vitro Generation of Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature from Murine Induced Pluripotent Stem Cells. *Stem Cell Reports* 2017; 8: 919-932 [PMID: 28366456 DOI: 10.1016/j.stemcr.2017.03.001]
- 41 Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FF, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. *Circulation* 2010; 121: 1113-1123 [PMID: 20176987 DOI: 10.1161/CIRCULATIONAHA.109.898312]
- 42 Giuliani M, Oudrhiri N, Noman ZM, Vernochet A, Chouaib S, Azzarone B, Durrbach A, Bennaceur-Griscelli A. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. *Blood* 2011; 118: 3254-3262 [PMID: 21803852 DOI: 10.1182/blood-2010-12-325324]
- 43 Liu Y, Goldberg AJ, Dennis JE, Gronowicz GA, Kuhn LT. One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. *PLoS One* 2012; 7: e33225 [PMID: 22457746 DOI: 10.1371/journal.pone.0033225]
- 44 Zou L, Luo Y, Chen M, Wang G, Ding M, Petersen CC, Kang R, Dagnaes-Hansen F, Zeng Y, Lv N, Ma Q, Le DQ, Besenbacher F, Bolund L, Jensen TG, Kjems J, Pu WT, Bünger C. A simple method for deriving functional MSCs and applied for osteogenesis in 3D scaffolds. *Sci Rep* 2013; 3: 2243 [PMID: 23873182 DOI: 10.1038/srep02243]
- 45 Hynes K, Menicanin D, Mrozik K, Gronthos S, Bartold PM. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. *Stem Cells Dev* 2014; 23: 1084-1096 [PMID: 24367908 DOI: 10.1089/scd.2013.0111]
- 46 Jeong J, Shin K, Lee SB, Lee DR, Kwon H. Patient-tailored application for Duchene muscular dystrophy on mdx mice based induced mesenchymal stem cells. *Exp Mol Pathol* 2014; 97: 253-258 [PMID: 25102299 DOI: 10.1016/j.yexmp.2014.08.001]
- 47 Hu GW, Li Q, Niu X, Hu B, Liu J, Zhou SM, Guo SC, Lang HL, Zhang CQ, Wang Y, Deng ZF. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. *Stem Cell Res Ther* 2015; 6: 10 [PMID: 26268554 DOI: 10.1186/scrt546]
- 48 Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, Bünger C, Bolund L, Luo Y. Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity

and chondrogenicity but less adipogenicity. *Stem Cell Res Ther* 2015; 6: 144 [PMID: 26282538 DOI: 10.1186/s13287-015-0137-7]

49 Lian Q, Zhang Y, Liang X, Gao F, Tse HF. Directed Differentiation of Human-Induced Pluripotent Stem Cells to Mesenchymal Stem Cells. *Methods Mol Biol* 2016; 1416: 289-298 [PMID: 27236679 DOI: 10.1007/978-1-4939-3584-0\_17]

50 Gao WX, Sun YQ, Shi J, Li CL, Fang SB, Wang D, Deng XQ, Wen W, Fu QL. Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells. *Stem Cell Res Ther* 2017; 8: 48 [PMID: 28253916 DOI: 10.1186/s13287-017-0499-0]

51 Nachlas ALY, Li S, Jha R, Singh M, Xu C, Davis ME. Human iPSC-derived mesenchymal stem cells encapsulated in PEGDA hydrogels mature into valve interstitial-like cells. *Acta Biomater* 2018; 71: 235-246 [PMID: 29505894 DOI: 10.1016/j.actbio.2018.02.025]

52 Wang D, Sun YQ, Gao WX, Fan XL, Shi JB, Fu QL. An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells. *Cell Transplant* 2018; 27: 1340-1351 [PMID: 30056763 DOI: 10.1177/0963689718780194]

53 Wang LT, Jiang SS, Ting CH, Hsu PJ, Chang CC, Sytwu HK, Liu KJ, Yen BL. Differentiation of Mesenchymal Stem Cells from Human Induced Pluripotent Stem Cells Results in Downregulation of c-Myc and DNA Replication Pathways with Immunomodulation Toward CD4 and CD8 Cells. *Stem Cells* 2018; 36: 903-914 [PMID: 29396902 DOI: 10.1002/stem.2795]

54 McGrath M, Tam E, Sladkova M, AlManaie A, Zimmer M, de Peppo GM. GMP-compatible and xeno-free cultivation of mesenchymal progenitors derived from human-induced pluripotent stem cells. *Stem Cell Res Ther* 2019; 10: 11 [PMID: 30635059 DOI: 10.1186/s13287-018-1119-3]

55 Eto S, Goto M, Soga M, Kaneko Y, Uehara Y, Mizuta H, Era T. Mesenchymal stem cells derived from human iPS cells via mesoderm and neuroepithelium have different features and therapeutic potentials. *PLoS One* 2018; 13: e0200790 [PMID: 30044827 DOI: 10.1371/journal.pone.0200790]

56 Ahfeldt T, Schinzel RT, Lee YK, Hendrickson D, Kaplan A, Lum DH, Camahort R, Xia F, Shay J, Rhee EP, Clish CB, Deo RC, Shen T, Lau FH, Cowley A, Mowrer G, Al-Siddiqi H, Nahrendorf M, Musunuru K, Gerszten RE, Rinn JL, Cowan CA. Programming human pluripotent stem cells into white and brown adipocytes. *Nat Cell Biol* 2012; 14: 209-219 [PMID: 22246346 DOI: 10.1038/ncb2411]

57 Chen YS, Pelekanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. *Stem Cells Transl Med* 2012; 1: 83-95 [PMID: 23197756 DOI: 10.5966/sctm.2011-0022]

58 Villa-Diaz LG, Brown SE, Liu Y, Ross AM, Lahann J, Parent JM, Krebsbach PH. Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. *Stem Cells* 2012; 30: 1174-1181 [PMID: 22415987 DOI: 10.1002/stem.1084]

59 Wei H, Tan G, Manasi, Qiu S, Kong G, Yong P, Koh C, Ooi TH, Lim SY, Wong P, Gan SU, Shim W. One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. *Stem Cell Res* 2012; 9: 87-100 [PMID: 22683798 DOI: 10.1016/j.scr.2012.04.003]

60 Shao K, Koch C, Gupta MK, Lin Q, Lenz M, Laufs S, Denecke B, Schmidt M, Linke M, Hennies HC, Hescheler J, Zenke M, Zechner U, Šarić T, Wagner W. Induced pluripotent

mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. *Mol Ther* 2013; 21: 240-250 [PMID: 23032973 DOI: 10.1038/mt.2012.207]

61 Miao Q, Shim W, Tee N, Lim SY, Chung YY, Ja KP, Ooi TH, Tan G, Kong G, Wei H, Lim CH, Sin YK, Wong P. iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium. *J Cell Mol Med* 2014; 18: 1644-1654 [PMID: 24974908 DOI: 10.1111/jcmm.12351]

62 Karam M, Younis I, Elareer NR, Nasser S, Abdelalim EM. Scalable Generation of Mesenchymal Stem Cells and Adipocytes from Human Pluripotent Stem Cells. *Cells* 2020; 9 [PMID: 32183164 DOI: 10.3390/cells9030710]

63 Huang X, Wang H, Xu Y. Induced Pluripotent Stem Cells (iPSC)-derived Mesenchymal Stem Cells (MSCs) Showed Comparable Effects in Repair of Acute Kidney Injury as Compared to Adult MSCs. *Urol J* 2020; 17: 204-209 [PMID: 32180215 DOI: 10.22037/uj.v0i0.5362]

64 Mitsuzawa S, Ikeguchi R, Aoyama T, Ando M, Takeuchi H, Yurie H, Oda H, Noguchi T, Ohta S, Zhao C, Ikeya M, Matsuda S. Induced pluripotent stem cell-derived mesenchymal stem cells prolong hind limb survival in a rat vascularized composite allotransplantation model. *Microsurgery* 2019; 39: 737-747 [PMID: 31471984 DOI: 10.1002/micr.30507]

65 Ouchi T, Morikawa S, Shibata S, Fukuda K, Okuno H, Fujimura T, Kuroda T, Ohyama M, Akamatsu W, Nakagawa T, Okano H. LNGFR+THY-1+ human pluripotent stem cell-derived neural crest-like cells have the potential to develop into mesenchymal stem cells. *Differentiation* 2016; 92: 270-280 [PMID: 27178356 DOI: 10.1016/j.diff.2016.04.003]

66 Fukuta M, Nakai Y, Kirino K, Nakagawa M, Sekiguchi K, Nagata S, Matsumoto Y, Yamamoto T, Umeda K, Heike T, Okumura N, Koizumi N, Sato T, Nakahata T, Saito M, Otsuka T, Kinoshita S, Ueno M, Ikeya M, Toguchida J. Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. *PLoS One* 2014; 9: e112291 [PMID: 25464501 DOI: 10.1371/journal.pone.0112291]

67 Zhao Q, Gregory CA, Lee RH, Reger RL, Qin L, Hai B, Park MS, Yoon N, Clough B, McNeill E, Prockop DJ, Liu F. MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. *Proc Natl Acad Sci U S A* 2015; 112: 530-535 [PMID: 25548183 DOI: 10.1073/pnas.1423008112]

68 Sánchez L, Gutierrez-Aranda I, Ligerio G, Rubio R, Muñoz-López M, García-Pérez JL, Ramos V, Real PJ, Bueno C, Rodríguez R, Delgado M, Menendez P. Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. *Stem Cells* 2011; 29: 251-262 [PMID: 21732483 DOI: 10.1002/stem.569]

69 Barberi T, Willis LM, Socci ND, Studer L. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. *PLoS Med* 2005; 2: e161 [PMID: 15971941 DOI: 10.1371/journal.pmed.0020161]

70 Hwang NS, Varghese S, Lee HJ, Zhang Z, Ye Z, Bae J, Cheng L, Elisseeff J. In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. *Proc Natl Acad Sci U S A* 2008; 105: 20641-20646 [PMID: 19095799 DOI: 10.1073/pnas.0809680106]

71 Frobel J, Hemeda H, Lenz M, Abagnale G, Joussen S, Denecke B, Sarić T, Zenke M, Wagner W. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. *Stem Cell Reports* 2014; 3: 414-422 [PMID: 25241740 DOI: 10.1016/j.stemcr.2014.07.003]



- 72 Luzzani C, Neiman G, Garate X, Questa M, Solari C, Fernandez Espinosa D, García M, Errecalde AL, Guberman A, Scassa ME, Sevlever GE, Romorini L, Miriuka SG. A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement. *Stem Cell Res Ther* 2015; 6: 6 [PMID: 25582222 DOI: 10.1186/scrt540]
- 73 Medici D, Nawshad A. Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. *Matrix Biol* 2010; 29: 161-165 [PMID: 20018240 DOI: 10.1016/j.matbio.2009.12.003]
- 74 Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ. Epigenetic memory in induced pluripotent stem cells. *Nature* 2010; 467: 285-290 [PMID: 20644535 DOI: 10.1038/nature09342]
- 75 P M, S H, R M, M G, W S K. Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. *Open Orthop J* 2011; 5: 253-260 [PMID: 21966340 DOI: 10.2174/1874325001105010253]
- 76 Matteucci C, Balestrieri E, Argaw-Denboba A, Sinibaldi-Vallebona P. Human endogenous retroviruses role in cancer cell stemness. *Semin Cancer Biol* 2018; 53: 17-30 [PMID: 30317035 DOI: 10.1016/j.semcancer.2018.10.001]
- 77 Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. *Transfusion* 2007; 47: 1436-1446 [PMID: 17655588 DOI: 10.1111/j.1537-2995.2007.01220.x]
- 78 Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA* 2012; 308: 2369-2379 [PMID: 23117550 DOI: 10.1001/jama.2012.25321]
- 79 Atoui R, Chiu RC. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. *Stem Cells Transl Med* 2012; 1: 200-205 [PMID: 23197779 DOI: 10.5966/sctm.2011-0012]
- 80 Zheng YL. Some Ethical Concerns About Human Induced Pluripotent Stem Cells. *Sci Eng Ethics* 2016; 22: 1277-1284 [PMID: 26276162 DOI: 10.1007/s11948-015-9693-6]
- 81 Morrison M, Bell J, George C, Harmon S, Munsie M, Kaye J. The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks. *Regen Med* 2017; 12: 693-703 [PMID: 28976812 DOI: 10.2217/rme-2017-0068]
- 82 Deng XY, Wang H, Wang T, Fang XT, Zou LL, Li ZY, Liu CB. Non-viral methods for generating integration-free, induced pluripotent stem cells. *Curr Stem Cell Res Ther* 2015; 10: 153-158 [PMID: 25248676 DOI: 10.2174/1574888x09666140923101914]
- 83 Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and Safety Issues of Stem Cell-Based Therapy. *Int J Med Sci* 2018; 15: 36-45 [PMID: 29333086 DOI: 10.7150/ijms.21666]
- 84 Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from

mouse and human fibroblasts. *Nat Biotechnol* 2008; 26: 101-106 [PMID: 18059259 DOI: 10.1038/nbt1374]

85 Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. *Stem Cell Res Ther* 2018; 9: 63 [PMID: 29523213 DOI: 10.1186/s13287-018-0791-7]

86 Li Y, Cheng Q, Hu G, Deng T, Wang Q, Zhou J, Su X. Extracellular vesicles in mesenchymal stromal cells: A novel therapeutic strategy for stroke. *Exp Ther Med* 2018; 15: 4067-4079 [PMID: 29725359 DOI: 10.3892/etm.2018.5993]

87 Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol* 2013; 200: 373-383 [PMID: 23420871 DOI: 10.1083/jcb.201211138]

88 Rahimzadeh A, Mirakabad FS, Movassaghpour A, Shamsasenjan K, Karimineko S, Talebi M, Shekari A, Zeighamian V, Ghalhar MG, Akbarzadeh A. Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system. *Artif Cells Nanomed Biotechnol* 2016; 44: 559-570 [PMID: 25340260 DOI: 10.3109/21691401.2014.968823]

89 Li CL, Leng Y, Zhao B, Gao C, Du FF, Jin N, Lian QZ, Xu SY, Yan GL, Xia JJ, Zhuang GH, Fu QL, Qi ZQ. Human iPSC-MSC-Derived Xenografts Modulate Immune Responses by Inhibiting the Cleavage of Caspases. *Stem Cells* 2017; 35: 1719-1732 [PMID: 28520232 DOI: 10.1002/stem.2638]

90 Ng J, Hynes K, White G, Sivanathan KN, Vandyke K, Bartold PM, Gronthos S. Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells. *J Cell Biochem* 2016; 117: 2844-2853 [PMID: 27167148 DOI: 10.1002/jcb.25596]

91 Devito L, Klontzas ME, Cvoro A, Galleu A, Simon M, Hobbs C, Dazzi F, Mantalaris A, Khalaf Y, Ilic D. Comparison of human isogenic Wharton's jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulation. *Cell Death Dis* 2019; 10: 277 [PMID: 30894508 DOI: 10.1038/s41419-019-1498-0]

92 Fan XL, Zeng QX, Li X, Li CL, Xu ZB, Deng XQ, Shi J, Chen D, Zheng SG, Fu QL. Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF- $\kappa$ B in allergic rhinitis patients. *Stem Cell Res Ther* 2018; 9: 170 [PMID: 29921316 DOI: 10.1186/s13287-018-0896-z]

93 Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DS, Tse HF, Xu G, Lian Q, Shi J, Fu QL. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. *Stem Cells* 2012; 30: 2692-2699 [PMID: 22987325 DOI: 10.1002/stem.1241]

94 Fu QL, Chow YY, Sun SJ, Zeng QX, Li HB, Shi JB, Sun YQ, Wen W, Tse HF, Lian Q, Xu G. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. *Allergy* 2012; 67: 1215-1222 [PMID: 22882409 DOI: 10.1111/j.1398-9995.2012.02875.x.]

95 Zhong H, Fan XL, Fang SB, Lin YD, Wen W, Fu QL. Human pluripotent stem cell-derived mesenchymal stem cells prevent chronic allergic airway inflammation via TGF- $\beta$ 1-Smad2/Smad3 signaling pathway in mice. *Mol Immunol* 2019; 109: 51-57 [PMID: 30852246 DOI: 10.1016/j.molimm.2019.02.017]

96 Yang H, Aprecio RM, Zhou X, Wang Q, Zhang W, Ding Y, Li Y. Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: a pilot study. *PLoS One* 2014; 9: e100285 [PMID: 24979372 DOI: 10.1371/journal.pone.0100285]

97 Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S. Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse

Inflammatory Bowel Disease Model. *Stem Cells Transl Med* 2018; 7: 456-467 [PMID: 29635868 DOI: 10.1002/sctm.17-0305]

98 Cheng PP, Liu XC, Ma PF, Gao C, Li JL, Lin YY, Shao W, Han S, Zhao B, Wang LM, Fu JZ, Meng LX, Li Q, Lian QZ, Xia JJ, Qi ZQ. iPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation. *Stem Cells Dev* 2015; 24: 1793-1804 [PMID: 25867817 DOI: 10.1089/scd.2014.0488]

99 Sun YQ, Zhang Y, Li X, Deng MX, Gao WX, Yao Y, Chiu SM, Liang X, Gao F, Chan CW, Tse HF, Shi J, Fu QL, Lian Q. Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon- $\gamma$ -induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice. *Stem Cells* 2015; 33: 3452-3467 [PMID: 26175298 DOI: 10.1002/stem.2094]

100 Li X, Zhang Y, Liang Y, Cui Y, Yeung SC, Ip MS, Tse HF, Lian Q, Mak JC. iPSC-derived mesenchymal stem cells exert SCF-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells. *J Cell Mol Med* 2017; 21: 265-277 [PMID: 27641240 DOI: 10.1111/jcmm.12962]

101 Obara C, Takizawa K, Tomiyama K, Hazawa M, Saotome-Nakamura A, Gotoh T, Yasuda T, Tajima K. Differentiation and Molecular Properties of Mesenchymal Stem Cells Derived from Murine Induced Pluripotent Stem Cells Derived on Gelatin or Collagen. *Stem Cells Int* 2016; 2016: 9013089 [PMID: 27642306 DOI: 10.1155/2016/9013089]

102 Zhu Y, Wang Y, Zhao B, Niu X, Hu B, Li Q, Zhang J, Ding J, Chen Y, Wang Y. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. *Stem Cell Res Ther* 2017; 8: 64 [PMID: 28279188 DOI: 10.1186/s13287-017-0510-9]

103 Pan XH, Zhou J, Yao X, Shu J, Liu JF, Yang JY, Pang RQ, Ruan GP. Transplantation of induced mesenchymal stem cells for treating chronic renal insufficiency. *PLoS One* 2017; 12: e0176273 [PMID: 28445516 DOI: 10.1371/journal.pone.0176273]

104 Spitzhorn LS, Megges M, Wruck W, Rahman MS, Otte J, Degistirici Ö, Meisel R, Sorg RV, Oreffo ROC, Adjaye J. Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature. *Stem Cell Res Ther* 2019; 10: 100 [PMID: 30885246 DOI: 10.1186/s13287-019-1209-x]